141 related articles for article (PubMed ID: 38785213)
1. Effect of sustained measurable residue disease negativity and post-remission treatment selection on the prognosis of acute lymphoblastic leukemia in adults.
Yu J; Luo Y; Wang L; Wang T; Ye M; Chen J; Ni X; Chen L; Gao L; Yang J
Cancer Med; 2024 May; 13(10):e7310. PubMed ID: 38785213
[TBL] [Abstract][Full Text] [Related]
2. [Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk].
Li ZR; Zhao T; Liu YR; Wang YZ; Xu LP; Zhang XH; Wang Y; Jiang H; Chen YY; Chen H; Han W; Yan CH; Wang J; Jia JS; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):554-560. PubMed ID: 32397017
[No Abstract] [Full Text] [Related]
3. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
4. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia.
Ribera JM; Morgades M; Ciudad J; Montesinos P; Esteve J; Genescà E; Barba P; Ribera J; García-Cadenas I; Moreno MJ; Martínez-Carballeira D; Torrent A; Martínez-Sánchez P; Monsalvo S; Gil C; Tormo M; Artola MT; Cervera M; González-Campos J; Rodríguez C; Bermúdez A; Novo A; Soria B; Coll R; Amigo ML; López-Martínez A; Fernández-Martín R; Serrano J; Mercadal S; Cladera A; Giménez-Conca A; Peñarrubia MJ; Abella E; Vall-Llovera F; Hernández-Rivas JM; Garcia-Guiñon A; Bergua JM; de Rueda B; Sánchez-Sánchez MJ; Serrano A; Calbacho M; Alonso N; Méndez-Sánchez JÁ; García-Boyero R; Olivares M; Barrena S; Zamora L; Granada I; Lhermitte L; Feliu E; Orfao A
Blood; 2021 Apr; 137(14):1879-1894. PubMed ID: 33150388
[TBL] [Abstract][Full Text] [Related]
6. [Effect of Philadelphia Chromosome Karyotype and Allogeneic Hematopoietic Stem Cell Transplantation on Patients with Acute Lymphoblastic Leukemia].
Wang Y; Xu XM; Zhang M; Wang H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1397-1406. PubMed ID: 36208241
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for adolescent and adult Tlymphoblastic leukemia /lymphoma: a large cohort multicenter study in China.
Luo L; Jiao Y; Li Y; Yang P; Gao J; Huang S; Huang W; Wang J; Dong F; Ke X; Zou D; Gao C; Jing H
Ann Hematol; 2024 Jun; 103(6):2073-2087. PubMed ID: 38581546
[TBL] [Abstract][Full Text] [Related]
8. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
Zhang M; Fu H; Lai X; Tan Y; Zheng W; Shi J; Zhao Y; Lin M; He J; Cai Z; Luo Y; Huang H
PLoS One; 2016; 11(10):e0163599. PubMed ID: 27695097
[TBL] [Abstract][Full Text] [Related]
9. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study).
Nagafuji K; Miyamoto T; Eto T; Kamimura T; Taniguchi S; Okamura T; Ohtsuka E; Yoshida T; Higuchi M; Yoshimoto G; Fujisaki T; Abe Y; Takamatsu Y; Yokota S; Akashi K; Harada M
J Hematol Oncol; 2013 Feb; 6():14. PubMed ID: 23388549
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China.
Ding Z; Han MZ; Chen SL; Ma QL; Wei JL; Pang AM; Zhang XY; Liang C; Yao JF; Cao YG; Feng SZ; Jiang EL
Chin Med J (Engl); 2015 Aug; 128(15):2065-71. PubMed ID: 26228220
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xie M; Shi T; Jiang Q; Jia Y; Zhou D; Tong H; Jin J; Zhu HH
Cancer; 2023 May; 129(10):1523-1536. PubMed ID: 36882308
[TBL] [Abstract][Full Text] [Related]
13. Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia.
Combariza JF; Arango M; Díaz L; Agudelo C; Hernandez S; Madera AM; León G; Avila V; Bautista L; Valdés J; Orduz R; Mejía F; Moreno L; Ramirez C
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e365-e372. PubMed ID: 33277225
[TBL] [Abstract][Full Text] [Related]
14. Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study.
Yasuda S; Najima Y; Konishi T; Yamada Y; Nagata A; Takezaki T; Kaito S; Kurosawa S; Sakaguchi M; Harada K; Shingai N; Yoshioka K; Inamoto K; Mukae J; Toya T; Igarashi A; Shimizu H; Kobayashi T; Kakihana K; Sakamaki H; Kawamata N; Ohashi K; Doki N
Leuk Res; 2021 Sep; 108():106627. PubMed ID: 34062327
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease.
Bourlon C; Lacayo-Leñero D; Inclán-Alarcón SI; Demichelis-Gómez R
Curr Oncol Rep; 2018 Mar; 20(4):36. PubMed ID: 29577208
[TBL] [Abstract][Full Text] [Related]
16. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
[TBL] [Abstract][Full Text] [Related]
17. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
[TBL] [Abstract][Full Text] [Related]
18. [Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in the first complete remission].
Nagafuji K
Rinsho Ketsueki; 2023; 64(9):1144-1151. PubMed ID: 37899194
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].
Zhao T; Zhu HH; Wang J; Jia JS; Yang SM; Jiang H; Lu J; Chen H; Xu LP; Zhang XH; Jiang B; Ruan GR; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):10-16. PubMed ID: 28219218
[No Abstract] [Full Text] [Related]
20. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
